ALCiS Health Inc., a consumer health company specializing in pain relief and body therapy products that utilize unique drug delivery technologies, announced the availability of ALCiS Daily Relief, a topical pain cream engineered to provide fast relief from muscle and joint pain, including that associated with arthritis, backache, strains, sprains and bruises.
Efforts to define the abnormally activated areas in the brains of people with bipolar disorder could lead to new drug treatments and better coping strategies, investigators reported at the International Conference on Bipolar Disorder in Pittsburgh.
A promising new drug candidate that may be effective against both actively dividing and slow-growing Mycobacterium tuberculosis (M. tb) has begun testing in humans, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced today. The novel antibiotic, PA-824, may shorten the time needed to treat tuberculosis (TB), a contagious disease that claims approximately two million lives worldwide each year. In partnership with the non-profit New York-based Global Alliance for TB Drug Development (TB Alliance), NIAID contributed to the drug candidate?s preclinical safety and efficacy testing in animal models. Now, a clinical trial to assess PA-824?s safety, sponsored by the TB Alliance, has opened at a medical clinic in Lincoln, NE.
The Food and Drug Administration (FDA) announced the tentative approval of two applications for nevirapine tablets manufactured by Ranbaxy Laboratories Limited, Guragon, India and Aurobindo Pharma Limited, Hyderabad, India. These are the first generic versions of Viramune Tablets manufactured by Boehringer Ingelheim. These products will now be available for consideration for purchase under the President?s Emergency Plan for AIDS Relief (PEPFAR).
New research under the direction of Paul Khavari, MD, PhD, professor in the Program in Epithelial Biology at the Stanford University School of Medicine and chief of the dermatology service at the Veterans Affairs Palo Alto Healthcare System, shows a novel and more effective way of testing which mutations cause cancer and which are mere research distractions. The work is published in the June issue of Nature Genetics.
A drug that curbs appetite has been found to reduce a host of factors that contribute to type 2 diabetes – including elevated blood sugar levels, a study has shown.
Diabetic retinopathy has been found in nearly 8 percent of pre-diabetic participants in the Diabetes Prevention Program (DPP), according to a report presented today at the American Diabetes Association’s 65th Annual Scientific Sessions. Diabetic retinopathy, which can lead to vision loss, was also seen in 12 percent of participants with type 2 diabetes who developed diabetes during the DPP. No other long-term study has evaluated retinopathy in a population so carefully examined for the presence or development of type 2 diabetes.
A significantly lower risk of heart disease can now be added to the list of proven long-term benefits of tight glucose control in people with type 1 diabetes. Researchers announced this finding today at the annual scientific meeting of the American Diabetes Association after analyzing cardiovascular (CVD) events such as heart attack, stroke, and angina in patients who took part in the Diabetes Control and Complications Trial (DCCT) years ago.
An experimental pill that controls blood fats as well as blood sugar could be a better treatment for diabetics with high cholesterol even though side effects may be worse than current drugs, researchers said.
A review of 42 trials has shown that in most cases manual toothbrushes remove as much plaque as their expensive electronic counterparts, and protect just as well against inflamed gums. In fact, the only type of electric toothbrush more effective than a manual brush is that with a rotating-oscillating head.